[Three cases of gastric cancer treated by S-1 combined with docetaxel in place of cisplatin]

Hideaki Ganno; Yoshihisa Watayo; Hidetoshi Amagasa; Toshiya Ohhara; Kenichiroh Hataji; Norihito Kawasaki; Toshiaki Kurokawa; Katsunori Ami; Akira Fukuda; Takeshi Nagahama; Masahiro Ando; Kuniyoshi Arai

[Three cases of gastric cancer treated by S-1 combined with docetaxel in place of cisplatin]

Gan To Kagaku Ryoho. 2010 Nov;37(12):2458-60.

[Article in Japanese]

Authors

Hideaki Ganno¹, Yoshihisa Watayo, Hidetoshi Amagasa, Toshiya Ohhara, Kenichiroh Hataji, Norihito Kawasaki, Toshiaki Kurokawa, Katsunori Ami, Akira Fukuda, Takeshi Nagahama, Masahiro Ando, Kuniyoshi Arai

Affiliation

¹ Dept. of Surgery, Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital.

PMID: 21224605

Abstract

Although combination of S-1 and cisplatin (CDDP) is a standard therapy for advance or recurrent gastric cancer patients, there are some cases where a CDDP administration is difficult for patients. We here report three such cases of gastric cancer treated by S-1 and docetaxel (DOC) combination therapy. Based on our three cases, we believe that S-1 and DOC combination therapy could be suitable for outpatients showing safety and efficacy.

Publication types

Case Reports

MeSH terms

Aged
Antimetabolites, Antineoplastic / administration & dosage
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cisplatin / adverse effects
Docetaxel
Drug Combinations
Female
Humans
Male
Middle Aged
Oxonic Acid / administration & dosage
Stomach Neoplasms / drug therapy*
Taxoids / administration & dosage
Tegafur / administration & dosage

Substances

Antimetabolites, Antineoplastic
Antineoplastic Agents
Drug Combinations
Taxoids
S 1 (combination)
Tegafur
Docetaxel
Oxonic Acid
Cisplatin